Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dosta...

por Kristeleit, Rebecca, Mathews, Cara, Redondo, Andres, Boklage, Susan, Hanlon, Jennifer, Im, Ellie, Brown, Jubilee
Publicado 2022

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10

por Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.
Publicado 2019

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

por Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann
Publicado 2016

Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in...

por Colomban, Olivier, Swisher, Elizabeth M., Kristeleit, Rebecca, McNeish, Iain, Shapira-Frommer, Ronnie, Goble, Sandra, Lin, Kevin K., Maloney, Lara, Freyer, Gilles, You, Benoit
Publicado 2023

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy

por Milani, Andrea, Kristeleit, Rebecca, McCormack, Mary, Raja, Fharat, Luvero, Daniela, Widschwendter, Martin, MacDonald, Nicola, Mould, Tim, Olatain, Adeola, Hackshaw, Allan, Ledermann, Jonathan A
Publicado 2017

The Tumor Microenvironment of Clear-Cell Ovarian Cancer

por Devlin, Michael-John, Miller, Rowan, Laforets, Florian, Kotantaki, Panoraia, Garsed, Dale W., Kristeleit, Rebecca, Bowtell, David D., McDermott, Jacqueline, Maniati, Eleni, Balkwill, Frances R.
Publicado 2022

An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials

por Pinato, David J., Stavraka, Chara, Flynn, Michael J., Forster, Martin D., O'Cathail, Séan M., Seckl, Michael J., Kristeleit, Rebecca S., Olmos, David, Turnbull, Samantha J., Blagden, Sarah P.
Publicado 2014

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies

por Osborn, Gabriel, Stavraka, Chara, Adams, Rebecca, Sayasneh, Ahmad, Ghosh, Sharmistha, Montes, Ana, Lacy, Katie E, Kristeleit, Rebecca, Spicer, James, Josephs, Debra H, Arnold, James N, Karagiannis, Sophia N
Publicado 2021

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study

por Kristeleit, Rebecca, Moreno, Victor, Boni, Valentina, Guerra, Eva M, Kahatt, Carmen, Romero, Ignacio, Calvo, Emiliano, Basté, Neus, López-Vilariño, José A, Siguero, Mariano, Alfaro, Vicente, Zeaiter, Ali, Forster, Martin
Publicado 2021

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

por Shapiro, Geoffrey I., Kristeleit, Rebecca S., Burris, Howard A., LoRusso, Patricia, Patel, Manish R., Drew, Yvette, Giordano, Heidi, Maloney, Lara, Watkins, Simon, Goble, Sandra, Jaw‐Tsai, Sarah, Xiao, Jim J.
Publicado 2018

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

por Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca
Publicado 2019

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

por Bono, Petri, Massard, Christophe, Peltola, Katriina J, Azaro, Analía, Italiano, Antoine, Kristeleit, Rebecca S, Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik-Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V J, Rodon, Jordi A
Publicado 2020

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

por Kristeleit, Rebecca, Plummer, Ruth, Jones, Robert, Carter, Louise, Blagden, Sarah, Sarker, Debashis, Arkenau, Tobias, Evans, Thomas R. Jeffry, Danson, Sarah, Symeonides, Stefan N., Veal, Gareth J., Klencke, Barbara J., Kowalski, Mark M., Banerji, Udai
Publicado 2023

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

por Jones, Robert, Plummer, Ruth, Moreno, Victor, Carter, Louise, Roda, Desamparados, Garralda, Elena, Kristeleit, Rebecca, Sarker, Debashis, Arkenau, Tobias, Roxburgh, Patricia, Walter, Harriet S., Blagden, Sarah, Anthoney, Alan, Klencke, Barbara J., Kowalski, Mark M., Banerji, Udai
Publicado 2023

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

por Luke, Jason J., Fakih, Marwan, Schneider, Charles, Chiorean, E. Gabriela, Bendell, Johanna, Kristeleit, Rebecca, Kurzrock, Razelle, Blagden, Sarah P., Brana, Irene, Goff, Laura W., O’Hayer, Kevin, Geschwindt, Ryan, Smith, Michael, Zhou, Feng, Naing, Aung
Publicado 2023

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study

por Kristeleit, Rebecca, Leary, Alexandra, Delord, Jean Pierre, Moreno, Victor, Oaknin, Ana, Castellano, Daniel, Shappiro, Geoffrey I., Fernández, Cristian, Kahatt, Carmen, Alfaro, Vicente, Siguero, Mariano, Rueda, Daniel, Zeaiter, Ali, Awada, Ahmad, Santaballa, Ana, Zaman, Khalil, Sehouli, Jalid, Subbiah, Vivek
Publicado 2023

Detection of circulating tumour cell clusters in human glioblastoma

por Krol, Ilona, Castro-Giner, Francesc, Maurer, Martina, Gkountela, Sofia, Szczerba, Barbara Maria, Scherrer, Ramona, Coleman, Niamh, Carreira, Suzanne, Bachmann, Felix, Anderson, Stephanie, Engelhardt, Marc, Lane, Heidi, Evans, Thomas Ronald Jeffry, Plummer, Ruth, Kristeleit, Rebecca, Lopez, Juanita, Aceto, Nicola
Publicado 2018

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

por Davis, Elizabeth J, Martin-Liberal, Juan, Kristeleit, Rebecca, Cho, Daniel C, Blagden, Sarah P, Berthold, Dominik, Cardin, Dana B, Vieito, Maria, Miller, Rowan E, Hari Dass, Prashanth, Orcurto, Angela, Spencer, Kristen, Janik, John E, Clark, Jason, Condamine, Thomas, Pulini, Jennifer, Chen, Xuejun, Mehnert, Janice M
Publicado 2022

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

por Oaknin, Ana, Pothuri, Bhavana, Gilbert, Lucy, Sabatier, Renaud, Brown, Jubilee, Ghamande, Sharad, Mathews, Cara, O'Malley, David M., Kristeleit, Rebecca, Boni, Valentina, Gravina, Adriano, Banerjee, Susana, Miller, Rowan, Pikiel, Joanna, Mirza, Mansoor R., Dewal, Ninad, Antony, Grace, Dong, Yuping, Zografos, Eleftherios, Veneris, Jennifer, Tinker, Anna V.
Publicado 2023

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable...

por Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana
Publicado 2022